Central D-Ala2-Met5-enkephalinamide mu/delta-opioid receptor activation reverses the anxiogenic-like properties of cholecystokinin on locomotor and rearing activity in CD-1 mice.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Brain Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  PMID 12706244
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• d-Ala-met-enkephalin injection into the ventral tegmental area: effect on investigatory and spontaneous motor behaviour in the rat

  2004cited by this paper
• Localization of the δ‐opioid receptor and dopamine transporter in the nucleus accumbens shell: Implications for opiate and psychostimulant cross‐sensitization

  1999cited by this paper
• Cholecystokinin receptor agonists block the jumping behaviour precipitated in morphine-dependent mice by naloxone.

  1999cited by this paper
• Inhibition of the mesoamygdala dopaminergic pathway impairs the retrieval of conditioned fear associations.

  1999cited by this paper
• Serum beta-endorphin level in patients with depression on fluvoxamine.

  1999cited by this paper
• Peripheral stimulation of CCK-B receptors by BC264 induces a hyperexploration, dependent on the delta opioid system in the nucleus accumbens of rat.

  1999cited by this paper
• High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments.

  1999cited by this paper
• Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies.

  1999cited by this paper
• Brain mechanisms of social anxiety disorder.

  1998cited by this paper
• Cholecystokinergic innervation of nucleus accumbens subregions.

  1998cited by this paper
• Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour.

  1998cited by this paper
• Neural plasticity and emotional memory

  1998cited by this paper
• Opioid peptides and immunodysfunction in patients with major depression and anxiety disorders.

  1998cited by this paper
• Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model.

  1998cited by this paper
• Modulation of memory, reinforcement and anxiety parameters by intra-amygdala injection of cholecystokinin-fragments Boc-CCK-4 and CCK-8s.

  1998cited by this paper
• Inhibition of anxiety in rats by antisense to cholecystokinin precursor protein.

  1998cited by this paper
• Role of different neurotransmitter systems in the cholecystokinin octapeptide-induced anxiogenic response in rats.

  1997cited by this paper
• Opioid modulation of attention-related responses: peripheral-to-central progression and development of mu influence as learning occurs

  1997cited by this paper
• Opioid modulation of attention-related responses: delta-receptors modulate habituation and conditioned bradycardia

  1997cited by this paper
• CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins

  1997cited by this paper
• Nucleus accumbens lesions impair context, but not cue, conditioning in rats

  1997cited by this paper
• Anxiogenic behavior in the light-dark paradigm follwoing intraventricular administration of cholecystokinin-8S, restraint stress, or uncontrollable footshock in the CD-1 mouse.

  1997cited by this paper
• Effect of chronic mild stress and prolonged treatment with imipramine on the levels of endogenous Met-enkephalin in the rat dopaminergic mesolimbic system.

  1996cited by this paper
• Differential effects of delta- and mu-opioid receptor antagonists on the amphetamine-induced increase in extracellular dopamine in striatum and nucleus accumbens.

  1996cited by this paper
• Variations of motor activity following intraventricular (D-Pen2, D-Pen5)-enkephalin administration: interaction with acute uncontrollable foot-shock in mice.

  1996cited by this paper
• Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice

  1996cited by this paper
• Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system.

  1996cited by this paper
• Opposite role of delta 1- and delta 2-opioid receptors activated by endogenous or exogenous opioid agonists on the endogenous cholecystokinin system: further evidence for delta-opioid receptor heterogeneity.

  1996cited by this paper
• CCKA, but not CCKB, agonists suppress the hyperlocomotion induced by endogenous enkephalins, protected from enzymatic degradation by systemic RB 101.

  1995cited by this paper
• Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects

  1995cited by this paper
• Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists.

  1994cited by this paper
• Biological actions of cholecystokinin.

  1994cited by this paper
• Mesoaccumbens dopamine-opiate interactions in the control over behaviour by a conditioned reinforcer

  1994cited by this paper
• Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway

  1992cited by this paper
• Effects of CCK antagonists on CCK-induced suppression of locomotor activity in mice.

  1992cited by this paper
• Balance of glutamate and dopamine in the nucleus accumbens modulates self-stimulation behavior after injection of cholecystokinin and neurotensin in the rat brain.

  1992cited by this paper
• Evidence that cholecystokinin-enhanced retention is mediated by changes in opioid activity in the amygdala.

  1992cited by this paper
• Dopamine depletion produces augmented behavioral responses to a Mu‐, but not a delta‐opioid receptor agonist in the nucleus accumbens: Lack of a role for receptor upregulation

  1992cited by this paper
• Cholecystokinin Modulates the Release of Dopamine from the Anterior and Posterior Nucleus Accumbens by Two Different Mechanisms

  1991cited by this paper
• Cholecystokinin and anxiety.

  1990cited by this paper
• Post-trial NMDA receptor allosteric blockade differentially influences habituation of behavioral responses to novelty in the rat.

  1990cited by this paper
• Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens

  1990cited by this paper
• Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics.

  1990cited by this paper
• Cholecystokinin-Tetrapeptide Induces Panic Attacks in Patients with Panic Disorder *

  1990cited by this paper
• Antidepressant action of imipramine and iprindole in mice is enhanced by inhibitors of enkephalin-degrading peptidases.

  1989cited by this paper
• Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function.

  1989cited by this paper
• Centrally administered CCK-8 suppresses activity in mice by a "peripheral-type" CCK receptor.

  1989cited by this paper
• Ventral mesencephalic neurons containing both cholecystokinin‐ and tyrosine hydroxylase‐like immunoreactivities project to forebrain regions

  1989cited by this paper
• CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens.

  1989cited by this paper
• Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area.

  1987cited by this paper
• Sensitization occurs to the locomotor effects of morphine and the specific mu opioid receptor agonist, DAGO, administered repeatedly to the ventral tegmental area but not to the nucleus accumbens.

  1987cited by this paper
• Enkephalin release into the ventral tegmental area in response to stress: modulation of mesocorticolimbic dopamine.

  1987cited by this paper
• Opioid regulation of hypothalamic-pituitary-adrenal function in depression.

  1985cited by this paper
• Mesolimbic dopamine lesions produce an augmented behavioral response to enkephalin.

  1985cited by this paper
• Chronic antidepressant treatment increases enkephalin levels in n. accumbens and striatum of the rat.

  1985cited by this paper
• Clarification of the behavioral functions of peripheral and central cholecystokinin: two separate peptide pools.

  1985cited by this paper
• Plasma cortisol and beta-endorphin immunoreactivity in nonmajor and major depression.

  1984cited by this paper
• Peptidergic neurones

  1980cited by this paper

• A Dynorphin Theory of Depression and Bipolar Disorder

  2024cites this paper
• Dansyl-PQRamide, a putative antagonist of NPFF receptors, reduces anxiety-like behavior of ethanol withdrawal in a plus-maze test in rats.

  2009cites this paper
• Chapter 4.1 Peptide receptor ligands to treat anxiety disorders

  2008cites this paper
• Comparative analysis of the mechanisms of attack and defense among higher brain animals

  2006cites this paper
• Intracerebroventricular D-Pen2, D-Pen5-enkephalin administration soon after stressor imposition influences behavioral responsivity to a subsequent stressor encounter in CD-1 mice.

  2005cites this paper
• Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion.

  2005cites this paper
• Endogenous opiates and behavior: 2003.

  2004cites this paper
• Locomotor activity and behavior of mutant mice deleted for gastrin gene expression.

  2004cites this paper
• DELETED FOR GASTRIN GENE EXPRESSION

  2004cites this paper
• Differential startle reactivity following central CCK-8S and systemic Boc CCK-4 administration in mice: antecedent stressor history and testing condition.

  2003cites this paper